Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1200 Page Mill Road, Palo Alto, United States

ReformX Feb. 4 at 2:00 PM

$KOD is a clinical-stage biotech developing cancer therapies; it is a high-risk, binary investment based on the success of its early-stage clinical trials.

1 · Reply

Kyle7776 Feb. 4 at 11:06 AM

$KOD are march calls safe? When is glow 2 going to be released

1 · Reply

Snackdaddy Feb. 2 at 12:53 PM

$KOD getting so close to results and price down $9 maybe $10 today….bad news hedge happening?

1 · Reply

RandomInvestor777 Jan. 30 at 1:53 PM

$KOD calls so expensive

0 · Reply

Stekli27 Jan. 29 at 5:34 PM

$KOD From Monday on, MESI results could be announced any day. Feels like an appetizer before the main course is served. GL

0 · Reply

Cutlass Jan. 29 at 2:15 PM

$KOD One day this will launch ⏰

0 · Reply

OfficialStocktwitsUser Jan. 28 at 10:26 PM

$KOD RSI: 45.79, MACD: 0.1356 Vol: 1.20, MA20: 26.79, MA50: 25.13 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Ntense Jan. 28 at 6:23 PM

$KOD so quite on this board. Sleeping giant.

1 · Reply

Stekli27 Jan. 27 at 4:21 PM

$KOD Looks like classic rotation. Small orders (retail) selling into weakness while medium and large orders are net buyers. Inflow > outflow, yet price stays flat = quiet accumulation. Institutions don’t chase, they absorb. This kind of tape usually resolves higher once supply dries up.

0 · Reply

ZoeyTanner Jan. 23 at 8:38 PM

$KOD new day, new pain. In some far out way, think management gets even with low lifes with new BP partner

0 · Reply

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Jan 22, 2026, 10:26 AM EST - 13 days ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX LITE

Jan 12, 2026, 8:45 PM EST - 22 days ago

Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 8:19 PM EST - 27 days ago

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:26 PM EST - 6 weeks ago

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 16, 2025, 10:55 PM EST - 7 weeks ago

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 7 weeks ago

Kodiak Sciences Announces Proposed Public Offering of Common Stock

Nov 13, 2025, 4:05 PM EST - 2 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 12, 2025, 5:48 PM EST - 2 months ago

Kodiak Sciences to Present at Upcoming Investor Conferences

Nov 5, 2025, 7:00 AM EST - 3 months ago

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Oct 31, 2025, 12:01 PM EDT - 3 months ago

The Big 3: GOOGL, KOD, FTK

GOOG GOOGL FTK

Sep 15, 2025, 7:00 AM EDT - 5 months ago

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 5 months ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Aug 27, 2025, 10:40 AM EDT - 5 months ago

Harbour BioMed Reports 2025 Interim Results

Aug 27, 2025, 6:54 AM EDT - 5 months ago

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

Aug 19, 2025, 2:18 PM EDT - 6 months ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 13, 2025, 4:00 PM EDT - 6 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 7 months ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jun 25, 2025, 4:45 PM EDT - 7 months ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

May 29, 2025, 9:32 PM EDT - 8 months ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:15 PM EDT - 9 months ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 9 months ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Mar 27, 2025, 4:01 PM EDT - 11 months ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:39 PM EDT - 11 months ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 23, 2025, 8:08 PM EST - 1 year ago

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Feb 4, 2025, 7:30 AM EST - 1 year ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 7, 2025, 6:00 AM EST - 1 year ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:33 PM EST - 1 year ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Nov 14, 2024, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 11, 2024, 6:15 AM EST - 1 year ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 1 year ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

May 29, 2024, 4:36 PM EDT - 1 year ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 1 year ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Mar 28, 2024, 8:57 PM EDT - 2 years ago

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 6:30 AM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 2 years ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 6, 2023, 5:00 AM EST - 2 years ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 2 years ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Sep 8, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 7, 2023, 6:00 AM EDT - 2 years ago

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

ReformX Feb. 4 at 2:00 PM

$KOD is a clinical-stage biotech developing cancer therapies; it is a high-risk, binary investment based on the success of its early-stage clinical trials.

1 · Reply

Kyle7776 Feb. 4 at 11:06 AM

$KOD are march calls safe? When is glow 2 going to be released

1 · Reply

Snackdaddy Feb. 2 at 12:53 PM

$KOD getting so close to results and price down $9 maybe $10 today….bad news hedge happening?

1 · Reply

RandomInvestor777 Jan. 30 at 1:53 PM

$KOD calls so expensive

0 · Reply

Stekli27 Jan. 29 at 5:34 PM

$KOD From Monday on, MESI results could be announced any day. Feels like an appetizer before the main course is served. GL

0 · Reply

Cutlass Jan. 29 at 2:15 PM

$KOD One day this will launch ⏰

0 · Reply

OfficialStocktwitsUser Jan. 28 at 10:26 PM

0 · Reply

Ntense Jan. 28 at 6:23 PM

$KOD so quite on this board. Sleeping giant.

1 · Reply

Stekli27 Jan. 27 at 4:21 PM

0 · Reply

ZoeyTanner Jan. 23 at 8:38 PM

$KOD new day, new pain. In some far out way, think management gets even with low lifes with new BP partner

0 · Reply

Kelly12 Jan. 23 at 3:37 PM

$KOD time to nibble?

1 · Reply

Stekli27 Jan. 22 at 6:04 PM

$KOD MESI (ksi-101) February, Glow 2 (tarcocimab ksi-301) March. I assume, if the mesi will prove what was shared last year in July, we go up to 30 % already in Feb..

1 · Reply

RandomInvestor777 Jan. 22 at 5:02 PM

$KOD what are the major PH3 readouts that could 2x the share price?

0 · Reply

ZoeyTanner Jan. 22 at 2:46 PM

$KOD Take off, Wainwright upgrade raised target sizeable gains. Away she goes

0 · Reply

erevnon Jan. 22 at 1:08 PM

HC Wainwright & Co. maintains Kodiak Sciences $KOD at Buy and raises the price target from $26 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Harvo Jan. 20 at 2:44 PM

$KOD This

0 · Reply

Stekli27 Jan. 18 at 10:12 AM

$KOD This slide says more than a dozen charts. Real patient, baseline vs week 48, only 2 doses per year. That’s not curve fitting, that’s visible disease modification. If GLOW2 confirms GLOW1, DR becomes a real, scalable market. Treatment burden is the bottleneck and Kodiak is directly attacking it. A $15B+ retinal market coming.

0 · Reply

Merlintrader Jan. 16 at 7:59 PM

$KOD

0 · Reply

StockConsultant Jan. 15 at 2:20 PM

$KOD Kodiak Sciences stock, watch for a top of range breakout, target 38 area at https://stockconsultant.com/?KOD

0 · Reply

ZoeyTanner Jan. 15 at 12:44 PM

$KOD Makes cents that KOD bumped a little AH, however, the bid was for OCUL not KOD. Sanofi sniffing around for suitors. Should very well improve pps 52 week high for KOD today and Friday. M & A is well and moving bios

1 · Reply

Stauter Jan. 15 at 10:33 AM

@Stekli27

0 · Reply

Stekli27 Jan. 15 at 8:20 AM

$KOD

0 · Reply

Market Cap	1.21B
Revenue (ttm)	0.00
Net Income (ttm)	-176.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	338,830
Avg Vol	867,580
Day's Range	N/A - N/A
Shares Out	53.05M
Stochastic %K	19%
Beta	2.67
Analysts	Sell
Price Target	$32.86